Loading stock data…
ARVN
$10.11-0.08 (-0.79%)
Market ClosedLast close May 8
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arvinas, Inc. in the Healthcare sector is trading at $10.11. The stock is currently 30% below its 52-week high of $14.51, remaining 3.9% below its 200-day moving average. Technical signals show neutral RSI of 37 and bullish MACD crossover, explaining why ARVN maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 37) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$10.11
Potential Upside
5%
Whystock Fair Value$10.62
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus16 analysts
Buy
Mean target$15.06+49.0%
Range$6.00 – $24.00
Fundamentals
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degrad...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$682.70M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.98
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-16.74%
Volume
Today's trading volume
583,361
Recent News
Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of +9.09% and +1.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline
ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protein degraders gain speed as Arvinas scores landmark approval
Although excitement over the biotech’s “Protac” protein degrader is being tempered by narrower-than-expected clinical benefit, R&D in the field is heating up.
How The Arvinas (ARVN) Story Is Shifting With Vepdeg And ARV-102 Milestones
Arvinas’ fair value estimate sits at US$14.88 per share, with the latest model keeping this price target unchanged. That stability comes as Street research remains split, with analysts clustering in an US$11 to US$20 target range while weighing early Vepdeg approval, the Q4 model reset, and upcoming ARV-102 milestones. As you read on, you will see how these views connect and what to watch to stay on top of the evolving story around this stock. Analyst Price Targets don't always capture the...
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for a new partner to sell it.